Journal of Contemporary Psychotherapy

, Volume 39, Issue 2, pp 135–143

Sexual Side Effects of Antidepressant Medications: An Informed Consent Accountability Gap

Original Paper

Abstract

Sexual side effects of antidepressant medications are far more common than initially reported, and their scope, quality, and duration remain poorly captured in the literature. Antidepressant treatment emergent sexual dysfunctions may decrease clients’ quality of life, complicate psychotherapy, and damage the treatment alliance. Potential damage to the treatment alliance is greatest when clients have not been adequately informed of risks related to sexual side effects. It had previously been assumed that sexual side effects always resolve shortly after medications are discontinued. Emerging evidence, however, suggests that in some individuals, sexual dysfunction side effects may persist indefinitely. The authors argue that all psychologists should be well-informed about sexual side effects risks of antidepressant medications, should routinely conduct a pre-medication baseline assessment of sexual functioning, and take an active role in the informed consent process.

Keywords

Antidepressant sexual side effects SSRIs Sexual dysfunction Iatrogenic Informed consent 

References

  1. Aguirre, B. (1999). Fluoxetine and compulsive sexual behavior. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 943. doi:10.1097/00004583-199908000-00008.PubMedCrossRefGoogle Scholar
  2. American Psychiatric Association. (2000). Practice guidelines for the treatment of patients with major depressive disorder (revision). The American Journal of Psychiatry, 157(Suppl 4), 1–45.Google Scholar
  3. American Psychological Association board of Educational Affairs. (1995, December). Final report of the BEA working group to develop a level I curriculum for psychopharmacology education and training. Washington DC: Curriculum for Level I training in psychopharmacology.Google Scholar
  4. Antonuccio, D. O. (2007, April). Informed parental choice about anti depressants for their children. American Society for the Advancement of Pharmacotherapy Tablet, 8(1), 1, 6–7.Google Scholar
  5. Antonuccio, D. O., Danton, W. G., & McClanahan, T. M. (2003). Psychology in the prescription era: Building a firewall between marketing and science. The American Psychologist, 58, 1028–1043. doi:10.1037/0003-066X.58.12.1028.PubMedCrossRefGoogle Scholar
  6. Arafa, M., & Shamloul, R. (2006). Efficacy of sertraline hydrochloride in treatment of premature ejaculation: A placebo-controlled study using a validated questionnaire. International Journal of Impotence Research, 18, 534–538. doi:10.1038/sj.ijir.3901469.PubMedCrossRefGoogle Scholar
  7. Bahrick, A. (2006, September). Post SSRI sexual dysfunction. American Society for the Advancement of Pharmacotherapy Tablet, 7(3), 2–3, 10–11.Google Scholar
  8. Bahrick, A. (2008). Persistence of sexual dysfunction side effects after discontinuation of antidepressant medications: Emerging evidence. The Open Psychology Journal, 1, 42–50. doi:10.2174/1874350100801010042.CrossRefGoogle Scholar
  9. Balon, R. (2006). SSRI-associated sexual dysfunction. American Journal of Psychiatry, Sep:163(9), 1504–1509.CrossRefGoogle Scholar
  10. Barnett, J. E. (2007). Informed consent: Too much of a good thing or not enough? Seeking an understanding of informed consent. Professional Psychology: Research and Practice, 38(2), 179–182. doi:10.1037/0735-7028.38.2.179.CrossRefGoogle Scholar
  11. Barnett, J. E., & Neel, M. L. (2000). Must all psychologists study psychopharmacology? Professional Psychology: Research and Practice, 31(6), 619–627. doi:10.1037/0735-7028.31.6.619.CrossRefGoogle Scholar
  12. Berry, D. (2006). Informing people about the risks and benefits of medicines: Implications for the safe and effective use of medicinal products. Current Drug Safety, 1, 121–126. doi:10.2174/157488606775252638.PubMedCrossRefGoogle Scholar
  13. Bolton, J. M., Sareen, J., & Reiss, J. P. (2006). Genital anaesthesia persisting six years after sertraline discontinuation. Journal of Sex and Marital Therapy, 32(4), 327–330.PubMedCrossRefGoogle Scholar
  14. Burt, C.W., McCaig, L. F., & Rechtsteiner, E. A. (June, 2007). Ambulatory medical care utilization estimates for 2005. Advance Data from Vital and Health Statistics, Number 388. Retrieved from http://www.cdc.gov/nchs/data/ad/ad388.pdf. Accessed Jan 7, 2008.
  15. Chen, H., Reeves, J. H., Fincham, J. E., Kennedy, W. K., Dorfman, J. H., & Martin, B. C. (2006). Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among georgia medicaid enrollees in 2001. Journal of Clinical Psychiatry, 67(6), 972–982.PubMedGoogle Scholar
  16. Clayton, A. H., Keller, A., & McGarvey, E. L. (2006). Burden of phase-specific sexual dysfunction with SSRIs. Journal of Affective Disorders, 91(1), 27–32. doi:10.1016/j.jad.2005.12.007.PubMedCrossRefGoogle Scholar
  17. Clayton, A. H., & Montejo, A. (2006). Major depressive disorder, antidepressants, and sexual dysfunction. The Journal of Clinical Psychiatry, 67(Suppl. 6), 33–37. Review.PubMedGoogle Scholar
  18. Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., et al. (2002). Prevalence of sexual dysfunction among newer antidepressants. Journal of Clinical Psychiatry, 63(4), 357–366.PubMedGoogle Scholar
  19. Cohen, D. (2004, May). Needed: Critical thinking about psychiatric medications. Keynote Address, 4th International Conference on Social Work in Health and Mental Health. Quebec City. Retrieved from http://www.ahrp.org/about/CohenPsychMed0504.pdf.
  20. Cohen, D., & Jacobs, D. (2000, Winter). A model consent form for psychiatric drug treatment. Journal of Humanistic Psychology. Retrieved from http://ssri-research.com/informed_consent.
  21. Csoka, A. B., Bahrick, A. S., & Mehtonen, O. P. (2008). Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors (SSRIs). Journal of Sexual Medicine, 5, 227–233.PubMedGoogle Scholar
  22. Csoka, A. B., & Shipko, S. (2006). Persistent sexual side effects after SSRI discontinuation. Psychotherapy and Psychosomatics, 75(3), 187–188. doi:10.1159/000091777.PubMedCrossRefGoogle Scholar
  23. de Jong, T. R., Snaphaan, L. J., Pattij, T., Veening, J. G., Waldinger, M. D., Cools, A. R., et al. (2006). Effects of chronic treatment with fluvoxamine and paroxetine during adolescence on serotonin-related behavior in adult male rats. Eur Neuropsychopharmocological, 16(1), 39–48.CrossRefGoogle Scholar
  24. Dunivin, D. L., & Southwell, G. D. (2000). Psychopharmacology training in psychology internships: A brief curriculum. Professional Psychology: Research and Practice, 31, 610–614.CrossRefGoogle Scholar
  25. Galli, V. B., Raute, N. J., McConville, B. J., & McElroy, S. L. (1998). An adolescent male with multiple paraphilias sucessfully treated with fluoxetine. Journal of Child and Adolescent Psychopharmocology, 8, 195–197.CrossRefGoogle Scholar
  26. Goode, E. (2004, February). Stronger warning is urged on antidepressants for teenagers. New York Times, p. A12.Google Scholar
  27. Gouvêa, T. S., Morimoto, H. K., de Faria, M. J., Moreira, E. G., & Gerardin, D. C. (2008). Maternal exposure to the antidepressant fluoxetine impairs sexual motivation in adult male mice. Pharmacology, Biochemistry and Behavior, 90(3), 416–419.CrossRefGoogle Scholar
  28. Happell, B., Manias, E., & Roper, C. (2004). Wanting to be heard: Mental health consumers’ experiences of information about medication. International Journal of Mental Health Nursing, 13(4), 242–248.PubMedCrossRefGoogle Scholar
  29. Higgins, A., Barker, P., & Begley, C. M. (2006). Iatrogenic sexual dysfunction and the protective withholding of information: In whose best interest? Journal of Psychiatric and Mental Health Nursing, 13, 437–446.PubMedCrossRefGoogle Scholar
  30. Hu, X. H., Bull, S. A., Hunkeler, E. M., Ming, F., Lee, J. Y., Firemen, B., et al. (2004). Incidence and duration of side effects and those reported as bothersome with selective serotonin reuptake inhibitor treatment for depression: Patient report vs. physician estimate. Journal of Clinical Psychiatry, 65(7), 959–965.PubMedCrossRefGoogle Scholar
  31. Johnson-Greene, D. (2007). Informed consent: Too much of a good thing or not enough? Commentary: Evolving standards for informed consent: Is it time for an individualized and flexible approach? Professional Psychology: Research and Practice, 38(2), 183–184.Google Scholar
  32. Kafka, M. P. (1996). Therapy for sexual impulsivity: The paraphilias and paraphilia-related disorders. Psychiatric Times, XIII(6). Retrieved from http://www.psychiatrictimes.comp960627.html.
  33. Kauffman, R. P. (2008). Persistent sexual side effects after discontinuation of psychotropic medications. Primary Psychiatry, 15, 24.Google Scholar
  34. Kauffman, R. P., & Murdock, A. (2007). Prolonged post-treatment genital anesthesia and sexual dysfunction following discontinuation of citalopram and the atypical antidepressant nefazodone. The Open Women’s Health Journal, 1, 1–3.Google Scholar
  35. Landen, M., Hogberg, P., & Thase, M. E. (2005). Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Journal of Clinical Psychiatry, 66(1), 100–106.PubMedCrossRefGoogle Scholar
  36. Maciag, D., Coppinger, D., & Paul, I. A. (2006). Evidence that the deficit in sexual behavior in adult rats neonatally exposed to citalopram is a consequence of 5-HT(1) receptor stimulation during development. Brain Research, 1125, 171–175.PubMedCrossRefGoogle Scholar
  37. Michels, K. B. (1999). Problems assessing nonserious adverse drug reactions: Antidepressant drug therapy and sexual dysfunction. Pharmacotherapy, 19(4), 424–429.PubMedCrossRefGoogle Scholar
  38. Montejo, A. L., Gines, L., Izquierdo, J. A., & Rico-Villademoros, F. (2001). Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Journal of Clinical Psychiatry, 62(Suppl 3), 10–21.PubMedGoogle Scholar
  39. Montejo-Gonzalez, A. L., Llorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., et al. (1997). SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of Sex and Marital Therapy, 23(3), 176–194.PubMedGoogle Scholar
  40. Montgomery, S. S., Baldwin, D. S., & Riley, A. (2002). Antidepresant medications: A review of the evidence for drug-induced sexual dysfunction. Journal of Affective Disorders, 69(1–3), 119–140.PubMedCrossRefGoogle Scholar
  41. Osvath, P., Fekete, S., Voros, V., & Vitrai, J. (2003). Sexual dysfunction among patients treated with antidepressants: A Hungarian retrospective study. European Psychiatry, 18(8), 412–414.PubMedCrossRefGoogle Scholar
  42. Pachter, W. S., Fox, R. E., Zimbardo, P., & Antonuccio, D. O. (2007). Corporate financing and conflicts of interest: A primer for psychologists. American Psychologist, 62(9), 1005–1015.PubMedCrossRefGoogle Scholar
  43. Raz, A. (2005). Perspectives on the efficacy of antidepressants for child and adolescent depression. Public Library of Science: Medicine, 3(1), e9.Google Scholar
  44. Rivas-Vasquez, R. A., Rey, G. J., Blais, M. A., & Rivas-VAsquez, A. A. (2000). Sexual dysfunction associated with antidepressant treatment. Professional Psychology: Research and Practice, 31(6), 641–651.CrossRefGoogle Scholar
  45. Rutherford, B. R., Aizaga, K., Sneed, J., & Roose, S. (2007). A survey of psychiatry residents’ informed consent practices. Journal of Clinical Psychiatry, 68, 558–565.PubMedGoogle Scholar
  46. Safarinejad, M. R. (2007). Safety and efficacy of escitalopram in the treatment of premature ejaculation: A double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology, 27, 444–450.Google Scholar
  47. Safarinejad, M. R., & Hosseini, S. Y. (2006). Safety and efficacy of citalopram in the treatment of premature ejaculation: A double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research, 18, 164–169.PubMedCrossRefGoogle Scholar
  48. Sharko, A. M. (2004). Selective serotonin reuptake inhibitor-induced sexual dysfunction in adolescents: A review. Journal of the American Academy of Child and Adolescent Psychiatry, 43(9), 1071–1079. Review.CrossRefGoogle Scholar
  49. Shindel, A., Nelson, C., & Brandes, S. (2007). Urologist practice patterns in the management of premature ejaculation: A nationwide survey. Journal of Sexual Medicine, 5, 199–205.PubMedCrossRefGoogle Scholar
  50. VandenBos, G. R., & Williams, S. (2000). Is psychologists’ involvement in the prescribing of psychotropic medication really a new activity? Professional Psychology: Research and Practice, 31, 615–618.CrossRefGoogle Scholar
  51. Waldinger, M. D. (2007). Premature ejaculation: Definition and drug treatment. Drugs, 67(4), 547–568.PubMedCrossRefGoogle Scholar
  52. Weintraub, N., Cohen, D., Klipper-Aurbach, Y., Zadik, Z., & Dickerman, Z. (2002). Deareased growth during therapy with selective serotonin reuptake inhibitors. Archives of Pediatrics and Adolescent Medicine, 156(7), 696–701.Google Scholar
  53. Wise, E. H. (2007). Informed consent: Too much of a good thing or not enough? Commentary: Informed consent: Complexities and Meanings. Professional Psychology: Research and Practice, 38(2), 183–184.Google Scholar
  54. Zajecka, M. D., Mitchell, B. S., & Fawcett, J. (1997). Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Pharmacology Bulletin, 33(4), 755–760.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.University Counseling ServiceThe University of IowaIowa CityUSA

Personalised recommendations